Orchestra BioMed
OBIO
65 hedge funds and large institutions have $98.2M invested in Orchestra BioMed in 2026 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 16 closing their positions.
518% more call options, than puts
Call options by funds: $68K | Put options by funds: $11K
64% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 14
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
9% more capital invested
Capital invested by funds: $90.1M → $98.2M (+$8.12M)
3% more funds holding
Funds holding: 63 → 65 (+2)
1.03% more ownership
Funds ownership: 38.43% → 39.46% (+1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$3.82M |
| 2 |
Millennium Management
New York
|
+$1.95M |
| 3 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$934K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$209K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$194K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.51M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
-$725K |
| 3 |
Jane Street
New York
|
-$503K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$397K |
| 5 |
PA
Perceptive Advisors
New York
|
-$380K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
AQR Capital Management
Greenwich,
Connecticut
| – | -$67.6K | -16,290 | Closed |
|
77
Creative Planning
Overland Park,
Kansas
| – | -$67.6K | -16,290 | Closed |
|
|
VF
78
Virtu Financial
New York
| – | -$57K | -13,623 | Closed |
|
|
GCP
79
GSA Capital Partners
London,
United Kingdom
| – | -$45K | -10,773 | Closed |
|
|
HI
80
Harbour Investments
Madison,
Wisconsin
| – | -$8.25K | -1,988 | Closed |
|
81
Optiver Holding
Amsterdam,
Netherlands
| – | -$1.29K | -312 | Closed |
|
OBIO Hedge Fund Activity: Q1 2026 in Review
65 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q1 2026, worth a combined $98.2M — up 9% from $90.1M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new OBIO positions and 16 closed out — a net gain of 3 holders — while 23 added to existing stakes and 14 trimmed.
The largest buyer was Propel Bio Management, opening a new position worth an estimated $3.82M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $1.51M sold.
- 65 institutional investors held Orchestra BioMed (OBIO) as of Q1 2026, up from 63 in Q4 2025.
- Funds reported $98.2M of Orchestra BioMed stock for Q1 2026, up 9% quarter-over-quarter.
- 19 funds opened new Orchestra BioMed positions in Q1 2026 and 16 closed out, a net change of +3 holders.
- The largest Orchestra BioMed buyer in Q1 2026 was Propel Bio Management, an estimated $3.82M added.
- The largest Orchestra BioMed seller in Q1 2026 was T. Rowe Price Associates, an estimated $1.51M sold.
Based on aggregated 13F filings for Q1 2026.